ONO-AE2-227
ONO-AE2-227 is an orally active EP4 receptor antagonist. ONO-AE2-227 blocks PGE2-mediated EP4 signaling by competitively antagonizing PGE2-induced cAMP elevation, and binds to EP4/EP3 with mouse Ki values of 2.7/21 nM. ONO-AE2-227 reduces aberrant crypt foci and intestinal polyp development, and inhibits intestinal polyp formation. ONO-AE2-227 enhances LPS-induced TNF-alpha release from human alveolar macrophages by blocking endogenous PGE2, blocks PGE2-induced ICAM-1 expression and leukocyte-endothelial adhesion, and attenuates PGE2-induced monocyte adhesion to brain endothelial cells. ONO-AE2-227 can be used for research on colon cancer.
For research use only. We do not sell to patients.
- CAS No.: 357605-73-3
- Formula: C27H23NO3
- Molecular Weight:409.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
|
EP4 2.7 nM (Ki) |
EP2 21 nM (Ki) |
TNF-α |
In Vitro
ONO-AE2-227 antagonizes PGE2-induced cAMP accumulation in mouse recombinant EP4/CHO cells with a pIC50 of 8.0[1].
ONO-AE2-227 (2.7-21 nM) binds mouse EP4 with a Ki of 2.7 nM and mouse EP3 with a Ki of 21 nM in CHO cell binding assays, with 1000-fold lower affinity for mouse EP1, EP2, DP, FP, IP, and TP[2].
ONO-AE2-227 (10-160 nM) is a potent competitive EP4 antagonist (10 nM median inhibitory concentration for PGE2-induced cAMP increase) and a weak EP3 antagonist (160 nM IC50 for PGE2-induced calcium increase) in receptor-expressing cell assays[2].
ONO-AE2-227 (15 min) is a potent EP4 receptor antagonist (pKB 9.17) with high selectivity over EP2 in transfected HEK cells[3].
ONO-AE2-227 (10-1000 nM; 20 min before PGE2 and 24 h with LPS) in human MDMs acts as an EP4 antagonist that right-shifts PGE2 inhibition of LPS-induced TNF-α release with a non-simple-competitive slope of 0.53[3].
ONO-AE2-227 blocks PGE2-induced ICAM-1 expression in bEnd.3 brain endothelial cells[4].
ONO-AE2-227 (10 mM; 24 h) reduces PGE2-induced ICAM-1 protein expression in primary cultured mouse brain endothelial cells[4].
ONO-AE2-227 (10 mM; 24 h) eliminates PGE2-induced U937 monocyte adhesion to bEnd.3 brain endothelial cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
ONO-AE2-227 (300 ppm; p.o.; ad libitum; from 6 weeks of age for 7 weeks) reduced the total number of intestinal polyps in Min mice, with the most significant reduction in the distal small intestine[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6Cr (male, 6 weeks of age)[2]
-
Dosage:100 or 400 ppm in diet
-
Administration:p.o.; ad libitum; from the day before first AOM until week 5
-
Result:In AOM-treated mice (n = 8 per group), 400 ppm ONO-AE2-227 reduced ACFs/colon to 8.3 (67% of the AOM-alone group), and the mean number of ACs/focus was 1.5.
The 100 ppm ONO-AE2-227 group had 12.4 ACFs/colon and 1.5 mean ACs/focus and did not affect ACF formation.
No ACFs were observed in vehicle-injected mice with or without 400 ppm ONO-AE2-227.
-
Animal Model:C57BL/6J-Min/+ (female, 6 weeks of age)[2]
-
Dosage:300 ppm in diet
-
Administration:p.o.; ad libitum; from 6 weeks of age for 7 weeks
-
Result:In Min mice treated with 300 ppm ONO-AE2-227, total polyps/mouse were 42.2 (69% of the basal diet group).
By location, polyp numbers/mouse were: proximal small intestine 3.3 (83%), middle small intestine 14.2 (74%), distal small intestine 24.5 (65%), and colon 0.2 (40%).
The size distribution showed reduction in polyps measuring ≤1.0 mm in diameter but not those >1.0 mm in diameter.
Chemical Information
-
CAS No. 357605-73-3
-
Molecular Weight 409.49
-
Formula C27H23NO3
-
SMILES
O=C(O)C=1C=CC=CC1CC=2C=CC=CC2NC(=O)C(C3=CC=CC=4C=CC=CC43)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ONO-AE2-227 Related Classifications
HY-10952 Related Classifications
Powered by Bioz